News on lab-developed tests and emerging diagnostic technologies.
The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.
The company said it will use the funds to expand its menu of STI tests and launch its io rapid diagnostic platform into UK sexual health clinics.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
The decline reflects a drop off in sales of its ColonSentry colorectal cancer blood test and other diagnostics.
